PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.

The current findings indicate that PD-L1 and CD4+ helper T cells may be reasonable targets for improving survival through manipulating chemosensitivity, providing significant implications for combining immunotherapies into the therapeutic strategy for endometrial carcinoma.